These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 23233662)
1. Genome-wide study of methotrexate clearance replicates SLCO1B1. Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662 [TBL] [Abstract][Full Text] [Related]
2. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190 [TBL] [Abstract][Full Text] [Related]
4. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545 [TBL] [Abstract][Full Text] [Related]
5. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369 [TBL] [Abstract][Full Text] [Related]
6. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024 [TBL] [Abstract][Full Text] [Related]
7. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance. Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876 [TBL] [Abstract][Full Text] [Related]
9. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803 [TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803 [TBL] [Abstract][Full Text] [Related]
11. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733 [TBL] [Abstract][Full Text] [Related]
12. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521 [TBL] [Abstract][Full Text] [Related]
13. Effects of Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736 [No Abstract] [Full Text] [Related]
14. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298 [TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Yang JJ; Cheng C; Devidas M; Cao X; Campana D; Yang W; Fan Y; Neale G; Cox N; Scheet P; Borowitz MJ; Winick NJ; Martin PL; Bowman WP; Camitta B; Reaman GH; Carroll WL; Willman CL; Hunger SP; Evans WE; Pui CH; Loh M; Relling MV Blood; 2012 Nov; 120(20):4197-204. PubMed ID: 23007406 [TBL] [Abstract][Full Text] [Related]
16. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Murry DJ; Synold TW; Pui CH; Rodman JH Pharmacotherapy; 1995; 15(2):144-9. PubMed ID: 7624260 [TBL] [Abstract][Full Text] [Related]
17. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia. Wang SM; Zeng WX; Wu WS; Sun LL; Yan D Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187 [TBL] [Abstract][Full Text] [Related]